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Hepatic autoregulation: response of glucose production and glu-
coneogenesis to increased glycogenolysis. Am J Physiol Endocri-
nol Metab 292: E1265–E1269, 2007. First published January 9,
2007; doi:10.1152/ajpendo.00411.2006.—The effect of increased
glycogenolysis, simulated by galactose’s conversion to glucose, on
the contribution of gluconeogenesis (GNG) to hepatic glucose pro-
duction (GP) was determined. The conversion of galactose to glucose
is by the same pathway as glycogen’s conversion to glucose, i.e.,
glucose 1-phosphate3 glucose 6-phosphate3 glucose. Healthy men
(n  7) were fasted for 44 h. At 40 h, hepatic glycogen stores were
depleted. GNG then contributed 90% to a GP of 8
mol kg1 min1. Galactose, 9 g/h, was infused over the next 4 h.
The contribution of GNG to GP declined from 90% to 65%, i.e., by
2 mol kg1 min1. The rate of galactose conversion to blood
glucose, measured by labeling the infused galactose with [1-2H]galac-
tose (n  4), was also 2 mol kg1 min1. The 41st h GP rose by
1.5 mol kg1 min1 and then returned to 9 mol kg1 min1,
while plasma glucose concentration increased from 4.5 to 5.3 mM,
accompanied by a rise in plasma insulin concentration. Over 50% of
the galactose infused was accounted for in blood glucose and hepatic
glycogen formation. Thus an increase in the rate of GP via the
glycogenolytic pathway resulted in a concomitant decrease in the rate
of GP via GNG. While the compensatory response to the galactose
administration was not complete, since GP increased, hepatic auto-
regulation is operative in healthy humans during prolonged fasting.
liver; galactose; deuterium oxide
GLUCOSE IS PRODUCED BY LIVER, also to some extent by kidney,
and perhaps intestine. The amount produced is normally reg-
ulated to the needs of the body, with the brain being a major
user. The glucose is produced by two processes: glycogenol-
ysis and gluconeogenesis (GNG). An interaction between these
processes in liver, termed hepatic autoregulation or interregu-
lation (8), has been postulated. Thus production in the fasted
state has been found unchanged, whether GNG is increased in
normal subjects by infusing gluconeogenic precursors, or in-
hibited by ethanol administration in Type 2 diabetic subjects
(12, 16–18, 27, 36, 37). Also, in dogs, an inhibitor of glyco-
genolysis has been reported to enhance glucagon-stimulated
hepatic uptake of gluconeogenic precursors (31). However,
using another inhibitor, in a similar study, glycogenolysis
declined without a compensatory increase in GNG (8).
The biochemical reactions in glycogenolysis are glycogen
3 glucose 1-phosphate (G-1-P) 3 glucose 6-phosphate
(G-6-P) 3 glucose (Fig. 1). Initial reactions in the hepatic
utilization of galactose are galactose3 galactose 1-phosphate
3 UDP-galactose 3 UDP-glucose. The UDP-glucose can be
converted to glycogen, and hence to glucose via glycogenoly-
sis, or be directly converted to G-1-P, and hence glucose
without glycogen, as an intermediate (6, 22).
We asked, if glycogenolysis were increased in humans,
would there be a compensatory decrease in GNG, and, if so, to
what extent? Galactose was infused into subjects fasted 40 h.
Hepatic glycogen stores are then depleted, and most production
is by GNG. Glucose was formed from the galactose. Since
conversion of galactose to glucose is via the reactions of
glycogenolysis, i.e., G-1-P 3 G-6-P 3 glucose (Fig. 1), that
conversion served as a surrogate for increasing glucose forma-
tion by glycogenolysis.
MATERIALS AND METHODS
Subjects. Written, informed consent was obtained from 10 healthy,
normal male volunteers, ages 33–45 yr, with body mass indexes of
23.0–27.1 kg/m2. Our Institutional Research Boards reviewed and
approved the study.
Procedure. In seven of the subjects, glucose production (GP) was
measured using [6,6-2H2]glucose, and the contribution of GNG to GP
using 2H2O (25). The subjects were fasted for 44 h, beginning after
dinner on the first day of study. They had been on their regular diets
and were allowed to drink noncaloric fluids ad libitum during the fast.
At 5 PM on the second day, i.e., 21 h into the fast, they were admitted
to the Diabetes Research Centre of the Odense University Hospital.
Drinking of 2H2O was then begun. The dose, 5 ml/kg body water, was
intended to achieve a body water enrichment of 0.5%. Body water
weight was calculated at 60% of body weight (25). The dose was
drunk in four equal portions spaced 2 h apart, so that the last portion
was ingested at 11 PM. Neither dizziness, nausea, nor any other side
effect occurred. Fluids ingested after 11 PM were enriched to 0.5%
with 2H2O.
At 8 AM on the 3rd day, 36 h into the fast, a catheter was inserted
into a superficial vein of one hand for blood collection. Another
catheter was placed in a vein of the other hand, and through it a prime
of 750 mg of glucose composed of 166 mg of [6,6-2H2]glucose, 98%
2H enriched (Isotec, Miamisburg, OH), and 584 mg of unlabeled
glucose in 15 ml of water, sterile and negative for pyrogen, was
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infused rapidly. Then 500 mg of glucose composed of 100 mg of the
[6,6-2H2]glucose and 400 mg of unlabeled glucose, also at a concen-
tration of 5% in water, were infused hourly at a constant rate for the
next 8 h. A 5% water solution of D-galactose was infused at a rate of
9 g/h for the last 4 h. The study ended after the 44th h of fasting.
During those last 8 h, blood was collected at 0.5- to 1-h intervals for
measurements of plasma glucose, insulin, C-peptide, and glucagon
concentrations and 2H enrichments at carbons 2, 5, and 6 of the
glucose. Plasma was frozen until analyzed.
To measure the fraction of the infused galactose converted to blood
glucose, three other subjects and one of the seven subjects given 2H2O
and [6,6-2H]glucose were treated in the same way, except 2H2O and
[6,6-2H]glucose were not given. Instead, the D-galactose infused was
2H enriched to 3% at its carbon 1 by adding D-[1-2H]galactose, 98%
2H enriched (Omicron Biochemicals, South Bend, IN). Blood was
collected at hourly intervals from the 41st through the 44th h, for
measurement of the 2H enrichment at carbon 1 of the blood glucose.
Analyses. Plasma glucose concentrations were determined using a
glucose oxidase method (Beckman Glucose Analyzer I, Fullerton,
CA). Enrichments of the hydrogens bound to carbons 2, 5, and 6 of
blood glucose were determined as previously detailed (3, 25, 30).
Briefly, the supernatant, obtained after deproteinizing a blood sample
by ZnSO4 and Ba(OH)2 addition, was deionized by passage through
a column of AG1-X8 in the formate form over AG50 W-X8 in the
hydrogen form (Bio-Rad, Hercules, CA). The column was washed
with water, and the effluent evaporated to dryness. The residue was
applied to a Bio-Rad HPX-87P column in an HPLC system with water
at 80°C as solvent and a flow rate of 0.5 ml/min. Glucose eluted
between 15 and 17 min, and galactose between 18 and 20 min. The
quantity of galactose was one-twentieth or less than that of glucose.
The fraction containing the glucose peak was collected.
To determine 2H enrichments at carbon 6, an aliquot of the glucose
was oxidized with periodate. The formaldehyde formed, which con-
tained carbon 6 with its two hydrogens, was condensed with ammonia
to form hexamethylenetetramine (HMT). The HMT was assayed by
gas chromatography-mass spectrometry for mass m 2. To determine
the enrichment at carbon 2, carbon 1 of glucose in another aliquot was
removed to form ribulose 5-phosphate, which was reduced to a
mixture of arabitol 5-phosphate and ribitol 5-phosphate. These were
oxidized with periodate, yielding formaldehyde containing carbon 2
with its hydrogen. Glucose from another aliquot was oxidized to
remove its carbon 6. The resulting xylose was oxidized with periodate,
yielding carbon 5 with its hydrogen, again in formaldehyde. These
formaldehydes were converted to HMTs, which were assayed for mass
m  1. HMTs formed from [6,6-2H2]glucose and [1-2H]sorbitol of
known enrichments served as standards in the assays.
The fraction of galactose converted to glucose was determined by
reducing an aliquot of the infused galactose to galactitol and aliquots of
blood glucoses to sorbitol using sodium borohydride (4). These polyols,
purified using the HPLC system, were also oxidized with periodate. The
formaldehydes formed, which contain carbons 1 and 6 of the polyols with
their hydrogens, were converted to HMTs, which were also assayed for
m 1. Again, HMTs made from [1-2H]sorbitol with known enrichments
served as standards. 2H enrichment of the hydrogen bound to carbon 1
was calculated, taking into account that the formaldehyde formed from
the CH2OH group containing carbon 6 was unlabeled.
Plasma insulin and C-peptide concentrations were measured by a
two-site time-resolved immunofluorometric assay (Wallac Dy, Tuku,
Finland). Plasma glucagon concentration was measured by radioim-
munoassay (13).
Calculations. The percent contribution of GNG to GP (%GNG)
was set equal to 100 times the enrichment of the hydrogen bound to
carbon 5 of blood glucose, divided by the enrichment of the hydrogen
bound to carbon 2 (25). The percent contribution via the glycogeno-
lytic pathway (GLY) then equals 100  %GNG.
The rate of appearance (Ra) of glucose in blood in micromoles per
kilogram per minute was calculated using the equation (38):
Ra
F pVC2 C1/2	E2 E1/t2 t1	
E2 E1/2
where F is the 2H enrichment of the [6,6-2H2]glucose infused, times
the quantity of glucose infused in mol kg1 min1; pV is the
extracellular space occupied by glucose, taken to be 200 ml times
0.65  130 ml (14); C2 and C1 are the concentrations in mM of
glucose in the plasma for the time interval t2  t1 in minutes over
which the Ra is calculated; and E2 and E1 are the corresponding 2H
enrichments of the hydrogens at carbon 6 of plasma glucose at those
times. GP in micromoles per kilogram per minute was calculated by
subtracting the rate of infusion of the glucose from the Ra. The
quantities GNG and GLY contributed to GP were calculated for each
time interval, t2  t1, over which the GP was determined by multi-
plying the GP by the average of the percent contributions of GNG and
GLY to GP at times t2 and t1.
The fraction of GP derived from galactose, when [1-2H]galactose
was infused from the 41st through the 44th h of fasting, was set equal
to the 2H enrichment in the hydrogen bound to carbon 1 of blood
glucose collected at the end of the last hour of the infusion, divided by
the enrichment in the [1-2H]galactose infused (35).
Statistics. All results are given as means 
 SDs. Changes in rates
of GP with time were examined using a randomized block design in
which the subject was the block. Comparison of GP in specified time
intervals was accomplished using t-tests with contrasts, controlling for
the mean GP of the subject (20).
RESULTS
Glucose concentration did not change from the 36th to 40th h
(Table 1). Following the initiation of the galactose infusion,
glucose concentration increased from 4.5 to 5.3 mM and
then remained at that concentration. GP (Table 2) was 8
Fig. 1. Pathways of conversion of glycogen, galactose, and gluconeogenic
substrates to glucose. P, phosphate.
Table 1. Plasma glucose concentrations
Hour Plasma Glucose Concentration, mM
36 4.8
0.4
37 4.8
0.5
38 4.7
0.5
39 4.6
0.5
391⁄2 4.6
0.6
40 4.4
0.5
41 5.2
0.4
42 5.4
0.5
43 5.3
0.2
431⁄2 5.3
0.2
44 5.2
0.4
Values are means 
 SD; n  7.
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mol kg1 min1 before galactose infusion, increased by
1.5 mol kg1 min1 in the first 2 h of infusion, and then
declined to 9 mol kg1 min1. The increase in GP in the
first 2 h of infusion was statistically significant (t  5.12, df 
36, P  0.0001), and GP during the next 2 h remained higher
than that before infusion (t  2.86, df  36, P  0.01).
The percent contribution of GNG to GP was 90% before
galactose infusion, decreasing to 65% with infusion
(Table 3). The test for linear trend from before infusion to the
44th h was statistically significant (t  21.54, df  36, P 
0.0001), and an F-test for departure from linearity was not
significant.
The absolute amount GNG contributed to GP (Table 4) was
7 mol kg1 min1 before galactose infusion, rose tran-
siently in the first hour of galactose infusion, and then declined
to 6 mol kg1 min1. The decline in absolute GNG in the
first 2 h of galactose infusion was not statistically significant,
but the decline in the next 2 h was statistically significant (t 
5.96, df  36, P  0.0001). The absolute contribution of
GLY to GP was 1 mol kg1 min1 before infusion and
rose to 3 mol kg1 min1 on galactose infusion. The test
for linear trend from before infusion to the 44th h was statis-
tically significant (t  19.49, df  36, P  0.0001), and an
F-test for departure from linearity was not significant.
The 2H enrichment at carbon 1 of blood glucose increased
with time during the infusion of the [1-2H]galactose (Table 5).
At the end of the infusion, the 44th h of fasting, the enrichment
in the glucose was 24.6 
 1.5% of the enrichment in the
infused galactose.
Insulin and C-peptide concentrations increased about two-
fold upon galactose infusion (Table 6). A small decline in
glucagon concentration is suggested.
DISCUSSION
Only a small amount of glycogen remains in the liver at 40 h
of fasting (19, 29). At that time in our subjects, GNG contrib-
uted 90% to GP and glycogenolysis 10%. Glucose is
formed by GNG from gluconeogenic substrates via G-6-P, by
glycogenolysis, and from galactose via G-1-P conversion
G-6-P. Thus when galactose was infused, three sources were
available for the production of glucose, all via G-6-P. The
increase in GP on beginning the galactose infusion indicates
the sum of the quantities of glucose produced from those
sources, then exceeded that produced from GNG and glyco-
genolysis before infusion. During that time, there was conver-
sion of galactose to glucose without an equivalent decrease in
contribution from one or both of the other sources. The finding
that GP returning toward the preinfusion rate means that, after
that time, a compensatory reduction occurred. However, GP
was still 1 mol kg1 min1 more than before galactose
infusion, so the compensatory response was incomplete. Other
conditions have been reported in which a breakdown has
occurred in hepatic autoregulation (2, 21). The increase in GP
presumably was needed to satisfy increased glucose utilization
consequent to the 0.8 mM rise in plasma glucose concentra-
tion with the accompanying rise in insulin concentration.
The contributions of GNG and GLY to GP are estimated
from the ratio of enrichments of the hydrogen bound to carbons
5 and 2 of blood glucose. [2-2H]glucose is produced in the
presence of 2H2O from galactose and glycogen via GLY in the
isomerization of G-6-P with fructose 6-phosphate (F-6-P), i.e.,
G-1-P 3 G-6-P 3 F-6-P 3 [2-2H]G-6-P 3 [2-2H]glucose
(25). [2,5-2H]glucose is formed by GNG. Carbon 5 is labeled
in the hydration of phosphoenolpyruvate and the isomerization
of glycerol 3-phosphate with glyceraldehyde 3-phosphate
(GAP), and again at carbon 2 in the isomerization of F-6-P
with G-6-P. The decline in the percent contribution of GNG to
GP (Table 3), measured by the ratio of 2H bound to carbon 5
to carbon 2 of the glucose, then reflects the mixing of that
[2-2H]glucose formed via GLY with [2,5-2H]glucose produced
by GNG.
Since the contribution of GNG to GP decreased by 25%
(Table 3) at a GP of 8 mol kg1 min1, a decline of 2Table 3. Percent contribution of GNG to GP
Hour %GNG
38 89.2
8.1
391⁄2 90.2
6.5
40 90.7
5.9
41 79.6
5.5
42 72.0
4.8
43 69.3
3.8
431⁄2 66.7
5.2
44 64.4
6.9
Values are means 
 SD; n  7. GNG, gluconeogenesis; GP, glucose
production.
Table 4. Rates of GNG and GLY contributions to GP
Hour GNG GLY
38–391⁄2 7.52
1.29 0.92
0.73
391⁄2–40 7.13
1.14 0.80
0.58
40–41 8.36
1.16 1.50
0.72
41–42 7.14
0.63 2.30
0.65
42–43 6.09
1.04 2.53
0.63
43–431⁄2 6.22
0.99 2.94
0.70
431⁄2–44 5.88
0.72 3.14
0.80
Values are means 
 SD in mol  kg1  min1; n  7. GLY, glycogenolytic
pathway.
Table 2. Glucose production
Hour Glucose Production, mol  kg1  min1
38–391⁄2 8.44
1.60
391⁄2–40 7.93
1.45
40–41 9.85
1.61
41–42 9.44
1.02
42–43 8.61
1.46
43–431⁄2 9.16
1.47
431⁄2–44 9.01
1.10
Values are means 
 SD; n  7.
Table 5. 2H enrichments in blood glucose formed
from [1-2H]galactose
Hour 2H Enrichment, %
41 0.28
0.04
42 0.51
0.05
43 0.64
0.07
44 0.71
0.04
Infusate 2.88
0.04
Values are means 
 SD; n  4.
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mol kg1 min1 might have been expected. The decline of
only a little more than 1 mol may be explained by the
increase in GP of 1 mol on galactose infusion. Glucose
from galactose contributed 25% to GP, since the 2H enrich-
ment in blood glucose was25% of that in the [1-2H]galactose
infused (Table 5). Since GP was 9 mol kg1 min1
during galactose infusion, galactose then contributed 2
mol kg1 min1. In accord with that, the contribution of
GLY to GP rose 2 mol kg1 min1 above that before
galactose infusion. Not only did GNG decline on galactose
infusion, but the small contribution glycogenolysis made from
stored glycogen to GP before infusion, 1 mol kg1 min1,
could also have declined.
Estimates of GNG and GLY contributions can also be
affected by glycogen cycling (15, 23, 34) and transaldolase
exchange (23, 24). The contribution of glycogen cycling is
likely minimal, while the contribution of transaldolase may be
significant. Also, to the extent, if any, that [2,5-2H]G-6-P
formed via the gluconeogenic pathway was converted to gly-
cogen, GNG could be underestimated. Galactose conversion to
glucose via G-1-P and G-6-P could have inhibited that con-
version, perhaps resulting in its infusion in the apparent tran-
sient increase in GNG. The transaldolase catalyzed exchange
between F-6-P formed from the galactose with GAP, i.e.,
F-6-P  [2-2H]GAP 7 [5-2H]F-6-P  GAP, followed by its
isomerization to G-6-P and hence to [2,5-2H]glucose, could
result in some of the galactose converted to glucose appearing
to originate via GNG.
The contribution to GP of glucose formed from the galactose
could have been more than 25%, since the 2H enrichment in
blood glucose appears to be still rising (Table 4). Also
[1-2H]G-6-P formed from the [1-2H]galactose, before its con-
version to glucose, could have lost 2H in the pentose phosphate
cycle, i.e., 3[1-2H]G-6-P  3NADP 3 3CO2  2 G-6-P 
GAP  3NADP3H (26), and in its equilibration with mannose
6-phosphate, i.e., [1-2H]G-6-P 3 [1-2H]F-6-P 3 mannose
6-phosphate 3 F-6-P 3 G-6-P (4).
That amount of glucose released into the circulation to fulfill
the body’s needs results from the hydrolysis of G-6-P to
glucose, catalyzed by glucose 6-phosphatase (21, 28, 36). The
quantity each source of the G-6-P contributes to forming that
amount depends only on the relative contribution of each
source to the G-6-P. Contributions of the sources to the glucose
produced will then be in the same proportion as their contri-
butions to the formation of the G-6-P. As those contributions
change, so must the fluxes through the pathways by which the
G-6-P is generated change. Thus, in response to the increased
formation of G-6-P from galactose via GLY, there must have
been a compensatory reduction in the flux of gluconeogenic
substrates to G-6-P.
The mechanism by which the so-called hepatic autoregula-
tion is achieved is not well understood (8, 18, 21, 28). The
increase in insulin concentration upon galactose infusion was
probably due to the small rise in glucose concentration, since
galactose is reported not to stimulate insulin release from islets
(11). A decline in free fatty acid concentration could have
contributed to the decreased GNG (2, 5, 21), but under the
study conditions the decrease in free fatty acid concentration
was likely small (19). Also, while insulin can inhibit GNG, as
well as glycogenolysis, its increase seems unlikely to explain
the decrease in GNG’s contribution because of the relative
insensitivity of the gluconeogenic pathway to insulin (1, 7).
Conceivably, an intermediate in galactose’s metabolism could
have inhibited GNG, but no such inhibition has been reported.
Galactose 1-phosphate was reported to inhibit phosphoglu-
comutase in vitro, but that was in the absence of glucose
1,6-bisphosphate, and no inhibition was demonstrated in vivo
(32). Furthermore, inhibition of that enzyme would be ex-
pected to decrease glycogenolysis and not GNG. An initial
period of hepatic glycogenolysis was reported on intravenous
injection of a bolus of galactose into men fasted overnight,
perhaps due to an inhibition of UDP-glucose pyrophosphorylase
by UDP-galactose (9).
Recently, our laboratory reported a 2H-NMR procedure for
measuring enrichments of 2H from 2H2O at carbons 5 and 2 of
glucose (19). Measurements, made in the postabsorptive state
and after long-term fasting, were compared with measurements
made by the chemical procedure used in this study (3, 30).
Three men were treated the same way as in this study, i.e.,
galactose infused for 4 h beginning after 40 h of fasting and GP
estimated using [6,6-2H2]glucose, except the 2H2O was given
12 h after fasting was begun. GNG again declined from 94 

5% to 69 
 6%, following galactose infusion. GP was about
the same at 40 h, 9.2 
 0.6 mol kg1 min1, as 44 h of
fasting, 8.8 
 0.2 mol kg1 min1. The rate of glycogen
synthesis, measured using nuclear mass resonance spectrome-
try, was 3.1 
 0.6 mol kg1 min1. Thus, of the 10
mol kg1 min1 of galactose infused, over 50% can then be
accounted for in glucose and glycogen formation. Most of
the galactose infused would be expected to be taken up by
liver (6).
Sunehag and Haymond reported giving galactose to healthy
women fasted overnight (35). Doses of 7.5 and 22.5 g/h were
ingested over 2-h periods. At the end of that time, at both
doses, GP was 12 mol kg1 min1. At the higher dose,
galactose contributed 75% to GP. After an overnight fast,
before galactose infusion, GNG and glycogenolysis would be
expected to have each contributed 50% to GP (e.g., Refs. 1,
3, 5, 15). Therefore, the results at the higher dose provide
further support for a compensatory decline in contribution of
GNG when glucose is produced from galactose. In that study,
similar to the present study, plasma glucose concentration was
4.7 mM before and 5.1 mM after galactose ingestion, and there
was a small increase, about a doubling, in insulin concentra-
tion. When men, fasted overnight, ingested 50 g of galactose,
20% appeared in circulating glucose over the next 8 h, in
accord with our estimate of 25%, although under other condi-
Table 6. Insulin, C-peptide, and glucagon concentrations
Hour Insulin C-Peptide Glucagon
36 26
18 362
113 18.6
9.6
37 10
5 301
109 12.8
6.1
38 11
4 249
86 13.0
4.2
39 8
3 229
90 12.2
7.3
40 10
7 226
114 14.9
5.8
41 18
9 306
129 10.2
5.0
42 28
18 442
142 10.6
5.5
43 26
15 458
138 12.6
5.4
44 21
10 424
101 11.4
5.1
Values are means 
 SD in pM; n  7.
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tions. There was only a transient increase in plasma glucose
and insulin concentrations upon the galactose ingestion (10).
Inhibitors of hepatic phosphorylase have been considered for
possible use in the treatment of diabetics. To be effective, GP
could have to decline without a compensatory increase in
GNG. The report of Fosgerau et al. (8) suggests that that would
be the case. The present study suggests that there could be a
compensatory increase. That assumes the mechanism resulting
in a decrease in GNG when glycogenolysis is increased in
normal subjects, as simulated by galactose’s conversion to
glucose, operates in diabetic patients to increase GNG when
glycogenolysis is decreased.
In conclusion, galactose has been used as a surrogate for
glycogen as a source of hepatic GP, since both glycogen and
galactose are converted to glucose by the same reaction steps.
The contribution of GNG to GP by liver of healthy subjects,
depleted of glycogen by fasting, declined on galactose admin-
istration within a few hours. An increase in GLY, resulting in
a compensatory decrease in GNG, is in accord with the exis-
tence of a mechanism in liver by which GP is regulated for the
body’s needs as the substrate for GP change.
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